Potential therapeutic effect of low-dose paclitaxel in melanoma patients resistant to immune checkpoint blockade: A pilot study

Gebhardt, Christoffer; Simon, Sonja C. S.; Weber, Rebekka; Gries, Mirko; Mun, Dong Hun; Reinhard, Raphael; Holland‐Letz, Tim; Umansky, Viktor; Utikal, Jochen

doi:10.1016/j.cellimm.2020.104274

Cited by 15 publications

(3 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The ability of myeloid cells to orchestrate immune responses in the TME makes them an attractive therapeutic target. Low-dose chemotherapy has shown reduction of tumor MDSCs (109)(110)(111). MDSC differentiation with ATRA reduced their immune-suppressive function and enhanced efficacy of GD2-CART in preclinical models (112).…”

Section: Discussion: Overcoming the Immune-suppressive Tme In Act For...mentioning

confidence: 99%

Adoptive Cell Therapy in Pediatric and Young Adult Solid Tumors: Current Status and Future Directions

et al. 2022

View full text Add to dashboard Cite

Advances from novel adoptive cellular therapies have yet to be fully realized for the treatment of children and young adults with solid tumors. This review discusses the strategies and preliminary results, including T-cell, NK-cell and myeloid cell-based therapies. While each of these approaches have shown some early promise, there remain challenges. These include poor trafficking to the tumor as well as a hostile tumor microenvironment with numerous immunosuppressive mechanisms which result in exhaustion of cellular therapies. We then turn our attention to new strategies proposed to address these challenges including novel clinical trials that are ongoing and in development.

show abstract

Section: Discussion: Overcoming the Immune-suppressive Tme In Act For...mentioning

confidence: 99%

Adoptive Cell Therapy in Pediatric and Young Adult Solid Tumors: Current Status and Future Directions

et al. 2022

View full text Add to dashboard Cite

show abstract

“…As for immunotherapy, AIFCM have shown a variety of abilities to enhance immunotherapy including recruiting lymphocytes, reducing immunosuppressive cells and increasing the immune-enhancing cytokines, etc. Many clinical trials on the use of AIFCM such as paclitaxel 240 , 241 , curcumin 242 , 243 and lentinan 244 in immunotherapy like cancer vaccine therapy and immune checkpoint blockade therapy have been reported, and received enhanced therapeutic outcomes.…”

Section: Clinical Application Of Aifcm In Cancer Combination Therapymentioning

confidence: 99%

Active Ingredients from Chinese Medicine for Combination Cancer Therapy

Wang¹,

Li²,

Chen³

et al. 2023

Int. J. Biol. Sci.

View full text Add to dashboard Cite

Combination therapy against cancer has gained increasing attention because it can help to target multiple pathways to tackle oncologic progression and improve the limited antitumor effect of single-agent therapy. Chinese medicine has been studied extensively in cancer therapy and proven to be efficacious in many cases due to its wide spectrum of anticancer activities. In this review, we aim to summarize the recent progress of active ingredients from Chinese medicine (AIFCM) in combination with various cancer therapeutic modalities, including chemotherapy, gene therapy, radiotherapy, phototherapy and immunotherapy. In addition to highlighting the potential contribution of AIFCM in combination cancer therapy, we also elucidate the underlying mechanisms behind their synergistic effect and improved anticancer efficacy, thereby encouraging the inclusion of these AIFCM as part of effective armamentarium in fighting intractable cancers. Finally, we present the challenges and future perspectives of AIFCM combination therapy as a feasible and promising strategy for the optimization of cancer treatment and better clinical outcomes.

show abstract

“…Such chemotherapeutics as gemcitabine, 5-fluorouracil, paclitaxel, and doxorubicin were demonstrated to significantly reduce MDSC frequencies ( 116 ). Thus, low-dose paclitaxel could decrease the accumulation and immunosuppressive activity of tumor-infiltrating MDSCs in melanoma-bearing mice ( 117 ) and melanoma patients ( 118 ), leading to the inhibition of tumor progression. Moreover, the anti-CD33 monoclonal antibody gemtuzumab ozogamicin has recently been reported to deplete MDSCs, restore T cell immunity, and improve the efficiency of immunotherapy of various tumors, including melanoma ( 119 ).…”

Section: Targeting Mdscs In Melanoma Therapymentioning

confidence: 99%

Enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as a therapeutic target

Kurt¹,

Lasser²,

Arkhypov³

et al. 2023

Journal of Clinical Investigation

Self Cite

View full text Add to dashboard Cite

Despite the remarkable success of immune checkpoint inhibitors (ICIs) in melanoma treatment, resistance to them remains a substantial clinical challenge. Myeloid-derived suppressor cells (MDSCs) represent a heterogeneous population of myeloid cells that can suppress antitumor immune responses mediated by T and natural killer cells and promote tumor growth. They are major contributors to ICI resistance and play a crucial role in creating an immunosuppressive tumor microenvironment. Therefore, targeting MDSCs is considered a promising strategy to improve the therapeutic efficacy of ICIs. This Review describes the mechanism of MDSC-mediated immune suppression, preclinical and clinical studies on MDSC targeting, and potential strategies for inhibiting MDSC functions to improve melanoma immunotherapy.

show abstract

Potential therapeutic effect of low-dose paclitaxel in melanoma patients resistant to immune checkpoint blockade: A pilot study

Cited by 15 publications

References 47 publications

Adoptive Cell Therapy in Pediatric and Young Adult Solid Tumors: Current Status and Future Directions

Adoptive Cell Therapy in Pediatric and Young Adult Solid Tumors: Current Status and Future Directions

Active Ingredients from Chinese Medicine for Combination Cancer Therapy

Enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as a therapeutic target

Contact Info

Product

Resources

About